Compare CAPR & PCYO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CAPR | PCYO |
|---|---|---|
| Founded | 2005 | 1976 |
| Country | United States | United States |
| Employees | N/A | 44 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Water Supply |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 242.8M |
| IPO Year | 2011 | 1995 |
| Metric | CAPR | PCYO |
|---|---|---|
| Price | $33.11 | $10.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $41.38 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 50.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.50 |
| EPS | N/A | ★ 0.19 |
| Revenue | ★ $22,270,465.00 | $1,227,787.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17,308.50 | N/A |
| P/E Ratio | ★ N/A | $53.09 |
| Revenue Growth | N/A | ★ 171.54 |
| 52 Week Low | $4.30 | $9.65 |
| 52 Week High | $40.37 | $12.16 |
| Indicator | CAPR | PCYO |
|---|---|---|
| Relative Strength Index (RSI) | 71.31 | 35.37 |
| Support Level | $22.09 | $9.90 |
| Resistance Level | $40.37 | $10.65 |
| Average True Range (ATR) | 1.72 | 0.30 |
| MACD | 0.61 | -0.05 |
| Stochastic Oscillator | 71.08 | 8.73 |
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Pure Cycle Corp is a diversified land and water resource development company. The company designs, constructs, manages, operates, and maintains water and wastewater systems. The firm operates in three business segments namely Water and wastewater resource development, Land development, and the Single-Family Rental Segment. It generates maximum revenue from the Land development segment. The land resource development segment includes all the activities necessary to develop and sell finished lots.